ATE424461T1 - Modifizierte zytokine für krebs therapie - Google Patents

Modifizierte zytokine für krebs therapie

Info

Publication number
ATE424461T1
ATE424461T1 AT01916988T AT01916988T ATE424461T1 AT E424461 T1 ATE424461 T1 AT E424461T1 AT 01916988 T AT01916988 T AT 01916988T AT 01916988 T AT01916988 T AT 01916988T AT E424461 T1 ATE424461 T1 AT E424461T1
Authority
AT
Austria
Prior art keywords
cancer therapy
modified cytokine
cytokine
modified
homing
Prior art date
Application number
AT01916988T
Other languages
English (en)
Inventor
Angelo Corti
Original Assignee
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Raffaele Centro Fond filed Critical San Raffaele Centro Fond
Application granted granted Critical
Publication of ATE424461T1 publication Critical patent/ATE424461T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • C08L89/04—Products derived from waste materials, e.g. horn, hoof or hair
    • C08L89/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT01916988T 2000-02-15 2001-02-13 Modifizierte zytokine für krebs therapie ATE424461T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI000249A IT1317835B1 (it) 2000-02-15 2000-02-15 Citochine modificate per uso nella terapia del cancro.

Publications (1)

Publication Number Publication Date
ATE424461T1 true ATE424461T1 (de) 2009-03-15

Family

ID=11444017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01916988T ATE424461T1 (de) 2000-02-15 2001-02-13 Modifizierte zytokine für krebs therapie

Country Status (29)

Country Link
US (4) US7150869B2 (de)
EP (2) EP2080804A1 (de)
JP (1) JP4836384B2 (de)
KR (1) KR100888761B1 (de)
CN (2) CN1446261B (de)
AT (1) ATE424461T1 (de)
AU (1) AU784173C (de)
BG (1) BG65931B1 (de)
BR (1) BR0108391A (de)
CA (1) CA2399986C (de)
CY (1) CY1109034T1 (de)
CZ (1) CZ299486B6 (de)
DE (1) DE60137835D1 (de)
DK (1) DK1255845T3 (de)
EA (1) EA007838B1 (de)
ES (1) ES2322234T3 (de)
HK (1) HK1048649B (de)
HU (1) HU227894B1 (de)
IL (2) IL150984A0 (de)
IT (1) IT1317835B1 (de)
MX (1) MXPA02007899A (de)
NO (1) NO330913B1 (de)
PL (1) PL207263B1 (de)
PT (1) PT1255845E (de)
SI (1) SI1255845T1 (de)
SK (1) SK287550B6 (de)
UA (1) UA85365C2 (de)
WO (1) WO2001061017A2 (de)
ZA (1) ZA200206450B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309694B2 (en) 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7109303B2 (en) 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
WO2001062298A2 (en) 2000-02-24 2001-08-30 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
AU2006200762B2 (en) * 2000-02-24 2008-08-21 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
AU2003209755B2 (en) 2002-02-06 2007-11-22 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
EP1346729A1 (de) * 2002-03-19 2003-09-24 Cardiovascular Research Institute Maastricht Zielgerichtete Therapie der myokardialen Angiogenese durch CD13/APN
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
WO2004091551A2 (en) * 2003-03-31 2004-10-28 Greenville Hospital System Anti-tumor vasculature effects of human serum albumin derivatives
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
WO2006067633A2 (en) 2004-12-23 2006-06-29 Molmed Spa Conjugation product
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
RU2502518C2 (ru) * 2008-05-13 2013-12-27 Молмед С.П.А. Конъюгаты для лечения мезотелиомы
CN108314741B (zh) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法
EP3886824A1 (de) 2018-11-30 2021-10-06 Fondazione Centro San Raffaele Kombinierte behandlung von primärem lymphom des zentralnervensystems
EP3882257A1 (de) 2020-03-20 2021-09-22 Ospedale San Raffaele S.r.l. Ngr-konjugate und verwendungen davon
EP4490298A1 (de) 2022-03-09 2025-01-15 Ospedale San Raffaele S.r.l. Fusionsproteine und verwendungen davon
EP4647081A1 (de) 2024-05-07 2025-11-12 Hiroshi Arakawa Zelloberflächen-ig-beaidigte immunspeicherlöscher und verwendungen davon

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
CA2178476A1 (en) 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
EP0927045B1 (de) * 1996-09-10 2005-12-14 The Burnham Institute Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
US6576239B1 (en) * 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6759509B1 (en) * 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
AU9477398A (en) * 1997-09-10 1999-03-29 Burnham Institute, The Methods of identifying molecules that home to angiogenic vasculature in tumors
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.

Also Published As

Publication number Publication date
BG65931B1 (bg) 2010-05-31
IL150984A (en) 2011-04-28
JP2004520801A (ja) 2004-07-15
JP4836384B2 (ja) 2011-12-14
PT1255845E (pt) 2009-04-09
WO2001061017A3 (en) 2002-01-31
ZA200206450B (en) 2003-04-24
IL150984A0 (en) 2003-02-12
ES2322234T3 (es) 2009-06-18
WO2001061017A2 (en) 2001-08-23
HK1048649B (en) 2009-08-14
NO20023833L (no) 2002-10-15
CA2399986C (en) 2012-10-02
EP1255845A2 (de) 2002-11-13
AU784173B2 (en) 2006-02-16
MXPA02007899A (es) 2004-09-10
EA200200808A1 (ru) 2003-02-27
UA85365C2 (ru) 2009-01-26
ITMI20000249A0 (it) 2000-02-15
US7476721B2 (en) 2009-01-13
EP1255845B1 (de) 2009-03-04
US20050265965A1 (en) 2005-12-01
SK11512002A3 (sk) 2003-02-04
US20100196458A1 (en) 2010-08-05
US20030157055A1 (en) 2003-08-21
CN1853730A (zh) 2006-11-01
CY1109034T1 (el) 2014-07-02
CZ299486B6 (cs) 2008-08-13
HUP0300005A2 (hu) 2003-04-28
HU227894B1 (en) 2012-05-29
EA007838B1 (ru) 2007-02-27
SI1255845T1 (sl) 2009-08-31
US7150869B2 (en) 2006-12-19
CN1853730B (zh) 2013-07-24
PL207263B1 (pl) 2010-11-30
NO330913B1 (no) 2011-08-15
BR0108391A (pt) 2003-03-11
US20070041939A1 (en) 2007-02-22
KR20020089348A (ko) 2002-11-29
IT1317835B1 (it) 2003-07-15
CN1446261B (zh) 2010-05-05
CA2399986A1 (en) 2001-08-23
CN1446261A (zh) 2003-10-01
AU4413501A (en) 2001-08-27
ITMI20000249A1 (it) 2001-08-15
HUP0300005A3 (en) 2005-09-28
DE60137835D1 (de) 2009-04-16
US7622556B2 (en) 2009-11-24
SK287550B6 (sk) 2011-01-04
KR100888761B1 (ko) 2009-03-17
AU784173C (en) 2006-09-07
DK1255845T3 (da) 2009-06-22
BG106999A (bg) 2003-04-30
PL362670A1 (en) 2004-11-02
EP2080804A1 (de) 2009-07-22
NO20023833D0 (no) 2002-08-13
HK1048649A1 (en) 2003-04-11
CZ20023093A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
ATE424461T1 (de) Modifizierte zytokine für krebs therapie
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
BR0214029A (pt) Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
PT758248E (pt) Formulacoes para o factor ix
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
BR0211769A (pt) Combinações antineoplásicas
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
DE69520499D1 (de) Histidine und homohistidine derivate zur verwendung als protein farnesyltransferase hemmstoffe
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
TR200102308T2 (tr) Yüzey etkinliğine sahip yapay peptidler ve bunların yapay yüzey aktif maddelerin hazırlanmasında kullanımı
DE60122944D1 (de) Mikronisierter zolpidem Hemitartrat
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
BR9912327A (pt) Inibidores da uroquinase
NO20031860D0 (no) Kahalaolid F
ATE431742T1 (de) Modifizierte zytokine für krebs therapie
EP1364657A4 (de) Mittel gegen tumoren in hämatopoetischen organen
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
ATE407217T1 (de) Hochexpression und herstellung von recombinanter s-adenosyl homocysteinase mit hochspezifischer aktivität und verbesserte testverfahren für s- adenosylmethionine (sam)
TR200302193T4 (tr) Kombinasyon kemoterapisi.
BR0214244A (pt) Uso de uma ascomicina
DE60141169D1 (de) Verwendung einer zusammensetzung mit n-acetylcystein zur konditionierung von stammzellen
ECSP003404A (es) Solucion acuosa estable de em 12 y procedimiento de preparacion de dicha solucion

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1255845

Country of ref document: EP